Hendrik Nogai M.D.: "Hello and dzień dobry. My name is Hendrik Nogai. I am the Chief Medical Officer at Ryvu Therapeutics. Ryvu Therapeutics is a clinical stage biotech company based in Krakow in Poland. We are currently developing two clinical assets one is a CDK8/CDK19 pathway inhibitor called RVU120. The second one is a dual PIM FLT3 inhibitor called SEL24. In addition we also have a productive early pipeline focused on synthetic lethality as well as immunooncology. Today the Ryvu team is in Madrid at the EHA meeting in 2024.
The EHA meeting is a well known meeting of the European Hematology Association. We are very proud that we can present progress of our clinical asset focused on RVU120. So we are presenting a progress update on two enrolling Phase 2 studies. The first one is called the RIVER-52 study. This study is enrolling patients with AML or high-risk MDS. The study is currently open in Poland, Italy, Spain, France and Canada so we have a global footprint and we are testing RVU120 as a single agent. We have a second phase to study that is enrolling in Poland and Italy. This study is called RIVER-81 and is testing RVU120 plus venetoclax in patients with AML. We are also looking forward to build on the very compelling preclinical data that we have in myelofibrosis models. We are currently planning to start another phase to study - the POTAMI-61 study which is scheduled to enroll the first patients in September 2024 in Poland and Italy which were test RVU120 as a single agent and in combination with ruxolitinib in patients with myelofibrosis. We are also happy to have the support of the EMSCO network which is about to start an investigative initiated study testing RVU120 as a single agent in patients with low-risk MDS which is scheduled to start in the third quarter of 2024. And we're happy to discuss data and engage in lots of discussions partners in the community here in Madrid".
Zapraszamy do zapoznania się z nagraniem.
